Comparative Pharmacology
Head-to-head clinical analysis: AMINOPHYLLIN versus LUFYLLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOPHYLLIN versus LUFYLLIN.
AMINOPHYLLIN vs LUFYLLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective phosphodiesterase inhibitor, increasing intracellular cAMP and cGMP; adenosine receptor antagonist, causing bronchodilation, CNS stimulation, and positive chronotropic/inotropic effects.
LUFYLLIN (dyphylline) is a xanthine bronchodilator that inhibits phosphodiesterase, increasing intracellular cAMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway hyperresponsiveness. It also antagonizes adenosine receptors.
Loading dose: 6 mg/kg IV over 30 minutes (if not on theophylline); maintenance: 0.5-0.7 mg/kg/hr IV continuous infusion for adults (non-smoking), higher for smokers (0.7-0.9 mg/kg/hr). Oral: immediate-release 200-400 mg every 6 hours; sustained-release 400-600 mg every 12 hours.
200-400 mg orally 3-4 times daily, not to exceed 1600 mg/day. Also available as 200 mg/mL injection, administer 200-400 mg IM or slow IV every 6-8 hours.
None Documented
None Documented
Clinical Note
moderateAminophylline + Gatifloxacin
"The metabolism of Gatifloxacin can be decreased when combined with Aminophylline."
Clinical Note
moderateAminophylline + Rosoxacin
"The metabolism of Rosoxacin can be decreased when combined with Aminophylline."
Clinical Note
moderateAminophylline + Levofloxacin
"The metabolism of Levofloxacin can be decreased when combined with Aminophylline."
Clinical Note
moderateAminophylline + Trovafloxacin
Terminal elimination half-life: 3–12 hours in adults (mean ~6 hours); prolonged in hepatic impairment, heart failure, or COPD (up to 30 hours); shorter in smokers (4–5 hours due to CYP1A2 induction); neonates: 20–40 hours.
6-8 hours in adults with normal hepatic and renal function. In neonates, half-life is prolonged to 20-30 hours. In patients with hepatic cirrhosis, half-life may extend to 20-30 hours. In congestive heart failure, half-life is prolonged to 12-20 hours.
Renal excretion of unchanged drug accounts for ~10%, with the remainder eliminated as metabolites (caffeine, 3-methylxanthine, 1-methyluric acid, 1,3-dimethyluric acid) via urine; minimal biliary/fecal elimination (<5%).
Primarily renal excretion of unchanged drug and metabolites. Approximately 50% is excreted unchanged in urine, with the remainder as metabolites (including 7-hydroxypropyltheophylline and 1,3-dimethyluric acid). Biliary/fecal elimination accounts for <10%.
Category C
Category C
Xanthine Bronchodilator
Xanthine Bronchodilator
"The metabolism of Trovafloxacin can be decreased when combined with Aminophylline."